Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Fluticasone furoate, umeclidinium, vilanterol

(Trelegy Ellipta®)

Trelegy Ellipta®

Drug updated on 11/4/2024

Dosage FormPowder (oral inhalation; fluticasone furoate/ umeclidinium/ vilanterol; 100/62.5/25 mcg, 200/62.5/25 mcg)
Drug ClassCorticosteroids, anticholinergics and beta-2 adrenergic agonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
  • Indicated for the maintenance treatment of asthma in patients aged 18 years and older.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
  • FF/UMEC/VI (Trelegy Ellipta) significantly increased trough FEV1 (forced expiratory volume in 1 s) at 24 weeks compared to other triple therapy options, except UMEC + FF/VI, in adults aged ≥40 years with moderate to very severe COPD.
  • FF/UMEC/VI showed statistically significant reductions in the annualized rate of combined moderate or severe exacerbations versus BUD/GLY/FOR and UMEC + FF/VI, as well as improvements in SGRQ scores and reductions in rescue medication use over 24 weeks.
  • BUD/GLY/FOR and BGF MDI demonstrated comparable efficacy to FF/UMEC/VI in improving lung function, reducing exacerbation rates, and enhancing health-related quality of life at both 24 and 52 weeks.
  • The safety profile of FF/UMEC/VI was not detailed in the reviewed studies.
  • BUD/GLY/FOR and BGF MDI were found to have a safety and tolerability profile comparable to other ICS/LAMA/LABA fixed-dose and open combination therapies, with no statistically significant differences in safety outcomes for BGF MDI.
  • There is no population types or subgroups information available in the reviewed studies.